EMEA-000117-PIP01-07-M07 - paediatric investigation plan

Ipilimumab
PIPHuman

Key facts

Invented name
  • Yervoy
  • Yervoy
Active Substance
Ipilimumab
Therapeutic area
Oncology
Decision number
P/0085/2015
PIP number
EMEA-000117-PIP01-07-M07
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except melanoma, nervous system, haematopoietic and lymphoid tissue)
Route(s) of administration
Intravenous use
Contact for public enquiries

Bristol-Myers Squibb Pharma EEIG 
E-mail: medical.information@bms.com 
Tel. +44 (0)1423 533610

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date
Compliance procedure number
EMEA-C-000117-PIP01-07-M07
Compliance opinion date
Compliance outcome
Positive

Decision

Share this page